22nd Century's Innovative Approach to Reduced Nicotine Cigarettes

22nd Century’s Commitment to Reduced Nicotine Products
Extensive Clinical Data Confirms VLN Reduced Nicotine Content Tobacco Aids Smoking Reduction and Increases Quit Attempts
Expanding Range of VLN Products Offers Non-Addictive Alternatives for Smoker Support
MOCKSVILLE, N.C. – 22nd Century Group, Inc. (Nasdaq: XXII), a front-runner in the fight against nicotine addiction’s impact on health, provides an important update concerning their Modified Risk Tobacco Product (MRTP) renewal process. The company’s flagship product, VLN® reduced nicotine content cigarettes, remain the first and only combustible cigarette approved by the FDA specifically designed to lower the adverse health effects associated with smoking.
The VLN® brand was initially authorized in December 2021, with the renewal due in 2026. Various brands are now introducing products featuring VLN® tobacco, which possesses 95% less nicotine than traditional cigarettes. An extensive compilation of independent clinical studies, alongside numerous peer-reviewed publications, have informed the FDA’s MRTP authorization, confirming that usage of VLN® cigarettes diminishes nicotine intake, facilitates smoking reduction, and enhances endeavors for quitting smoking.
The Importance of VLN in Tobacco Harm Reduction
As Larry Firestone, Chief Executive Officer of 22nd Century Group, remarked, “Our MRTP authorization for VLN® cigarettes represents a revolutionary milestone in the endeavor of Tobacco Harm Reduction. The FDA’s endorsement of reducing nicotine levels to non-addictive thresholds can transform smoking habits and boost public health.”
He continued, “We aim to provide smokers with a diverse array of low-nicotine options, fostering healthy decisions about tobacco use. The innovative range under the VLN® umbrella supports the notion of personalized health objectives and responsible nicotine consumption.”
The Future of VLN Cigarettes
Additionally, VLN® cigarettes uniquely comply with the FDA’s guidelines for low nicotine, following a proposed mandate initiated in early 2025. While the guidelines are not yet finalized, there is optimism that the FDA will commendably support the impending MRTP renewal for VLN®.
This renewal process aligns with 22nd Century’s relentless commitment to research and development focused on advancing the production of reduced nicotine content tobacco and facilitating the introduction of new VLN® products. The initiative provides tobacco users with healthier, non-addictive alternatives to traditional tobacco and new nicotine delivery systems that aim to promote prolonged nicotine dependence.
About 22nd Century Group
22nd Century Group stands as a pioneering enterprise devoted to nicotine harm reduction within the tobacco sector, empowering smokers to manage their nicotine intake effectively.
The VLN® cigarette was expertly crafted to deliver an authentic and familiar smoking experience while enabling users to take charge of their nicotine consumption. With 95% less nicotine compared to conventional cigarettes, VLN® has been demonstrated to facilitate significant reduction in nicotine intake.
Innovation Behind VLN Cigarettes
Rather than simply offering alternative nicotine delivery systems, the goal is to provide smokers a chance to control their nicotine use and make informed choices. Our proprietary formulations derive from comprehensive, patented tobacco technologies, ensuring that each product delivers robust flavor and high yield with substantially lower nicotine levels.
Furthermore, the extensive patent portfolio reinforces our unique position as the sole provider of low-nicotine combustible cigarettes across the United States and significant international markets. All these efforts reinforce our commitment to revolutionizing smoking habits and health outcomes.
Frequently Asked Questions
What makes VLN® cigarettes unique?
VLN® cigarettes are the first and only combustible tobacco products authorized by the FDA specifically designed to help smokers reduce and control nicotine intake.
How does reducing nicotine help smokers?
Reducing nicotine can decrease addiction levels, leading to lower consumption, less frequent smoking, and increased attempts to quit.
When is the renewal for VLN® due?
The MRTP renewal for VLN® is anticipated in December 2026.
What is included in 22nd Century’s research efforts?
The research focuses on advancing the development of reduced nicotine tobacco and expanding the range of VLN® products that serve as healthier alternatives for smokers.
How does 22nd Century Group aim to support smokers?
The company provides innovative low-nicotine options that empower smokers to control their nicotine consumption, promoting healthier choices and improved public health outcomes.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.